Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cellsSPIEKERMANN, Karsten; BAGRINTSEVA, Ksenia; SCHWAB, Ruth et al.Clinical cancer research. 2003, Vol 9, Num 6, pp 2140-2150, issn 1078-0432, 11 p.Article

A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemiaSPIEKERMANN, Karsten; BAGRINTSEVA, Ksenia; SCHOCH, Claudia et al.Blood. 2002, Vol 100, Num 9, pp 3423-3425, issn 0006-4971, 3 p.Article

KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factorKOHL, Tobias M; SCHNITTGER, Susanne; ELLWART, Joachim W et al.Blood. 2005, Vol 105, Num 8, pp 3319-3321, issn 0006-4971, 3 p.Article

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IVFABARIUS, Alice; LEITNER, Armin; JUNG-MUNKWITZ, Susanne et al.Blood. 2011, Vol 118, Num 26, pp 6760-6768, issn 0006-4971, 9 p.Article

NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS)SCHNEIDER, Friederike; HOSTER, Eva; BUSKE, Christian et al.Blood. 2009, Vol 113, Num 21, pp 5250-5253, issn 0006-4971, 4 p.Article

An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemiaMETZELER, Klaus H; HUMMEL, Manuela; MAHARRY, Kati et al.Blood. 2008, Vol 112, Num 10, pp 4193-4201, issn 0006-4971, 9 p.Article

FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L)BAGRINTSEVA, Ksenia; GEISENHOF, Stefanie; KERN, Ruth et al.Blood. 2005, Vol 105, Num 9, pp 3679-3685, issn 0006-4971, 7 p.Article

Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IVHEHLMANN, Rüdiger; MÜLLER, Martin C; SCHNITTGER, Susanne et al.Journal of clinical oncology. 2014, Vol 32, Num 5, pp 415-423, issn 0732-183X, 9 p.Article

Acute heart failure: When standard therapy fails - an interdisciplinary challengeLECHNER, Katharina E; POHL, Tilmann; KOLB, Hans Jochem et al.International journal of cardiology. 2011, Vol 147, Num 1, pp 160-162, issn 0167-5273, 3 p.Article

The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3SPIEKERMANN, Karsten; DIRSCHINGER, Ralf J; SCHWAB, Ruth et al.Blood. 2003, Vol 101, Num 4, pp 1494-1504, issn 0006-4971, 11 p.Article

High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemiaMETZELER, Klaus H; HEILMEIER, Bernhard; SAUERLAND, Maria C et al.Blood. 2012, Vol 120, Num 10, pp 2118-2126, issn 0006-4971, 9 p.Article

CBL Exon 8/9 Mutants Activate the FLT3 Pathway and Cluster in Core Binding Factor/11q Deletion Acute Myeloid Leukemia/ Myelodysplastic Syndrome SubtypesREINDL, Carola; QUENTMEIER, Hilmar; BOHLANDER, Stefan K et al.Clinical cancer research (Print). 2009, Vol 15, Num 7, pp 2238-2247, issn 1078-0432, 10 p.Article

ERG Expression Is an Independent Prognostic Factor and Allows Refined Risk Stratification in Cytogenetically Normal Acute Myeloid Leukemia: A Comprehensive Analysis of ERG, MN1, and BAALC Transcript Levels Using Oligonucleotide MicroarraysMETZELER, Klaus H; DUFOUR, Annika; BRAESS, Jan et al.Journal of clinical oncology. 2009, Vol 27, Num 30, pp 5031-5038, issn 0732-183X, 8 p.Article

Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemiaBENTHAUS, Tobias; SCHNEIDER, Friederike; SPIEKERMANN, Karsten et al.British journal of haematology. 2008, Vol 143, Num 2, pp 230-239, issn 0007-1048, 10 p.Article

KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survivalSCHNITTGER, Susanne; KOHL, Tobias M; HAFERLACH, Torsten et al.Blood. 2006, Vol 107, Num 5, pp 1791-1799, issn 0006-4971, 9 p.Article

SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AMLLEISCHNER, Hannes; ALBERS, Corinna; GRUNDLER, Rebekka et al.Blood. 2012, Vol 119, Num 17, pp 4026-4033, issn 0006-4971, 8 p.Article

Acute Myeloid Leukemia With Biallelic CEBPA Gene Mutations and Normal Karyotype Represents a Distinct Genetic Entity Associated With a Favorable Clinical OutcomeDUFOUR, Annika; SCHNEIDER, Friederike; WÖRMANN, Bernhard et al.Journal of clinical oncology. 2010, Vol 28, Num 4, pp 570-577, issn 0732-183X, 8 p.Article

Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia : A Study by the German Acute Myeloid Leukemia Cooperative GroupBÜCHNER, Thomas; BERDEL, Wolfgang E; GRIINEISEN, Andreas et al.Journal of clinical oncology. 2009, Vol 27, Num 1, pp 61-69, issn 0732-183X, 9 p.Article

Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia : a pilot study of the AMLCGBRAESS, Jan; SPIEKERMANN, Karsten; SCHMID, Christoph et al.Blood. 2009, Vol 113, Num 17, pp 3903-3910, issn 0006-4971, 8 p.Article

GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemiaGREIF, Philipp A; DUFOUR, Annika; DÖRGE, Petra et al.Blood. 2012, Vol 120, Num 2, pp 395-403, issn 0006-4971, 9 p.Article

RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genesGREIF, Philipp A; KONSTANDIN, Nikola P; BRAESS, Jan et al.Haematologica (Roma). 2012, Vol 97, Num 12, pp 1909-1915, issn 0390-6078, 7 p.Article

Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trialSTELIJES, Matthias; BEELEN, Dietrich W; SPIEKERMANN, Karsten et al.Haematologica (Roma). 2011, Vol 96, Num 7, pp 972-979, issn 0390-6078, 8 p.Article

Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR : clonal evolution is a limiting factorPAPADAKI, Christina; DUFOUR, Annika; SEIBL, Marlene et al.British journal of haematology. 2009, Vol 144, Num 4, pp 517-523, issn 0007-1048, 7 p.Article

Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AMLREINDL, Carola; BAGNNTSEVA, Ksenia; VEMPATI, Sridhar et al.Blood. 2006, Vol 107, Num 9, pp 3700-3707, issn 0006-4971, 8 p.Article

Deregulated expression of HOXB4 enhances the primitive growth activity of human hematopoietic cellsBUSKE, Christian; FEURING-BUSKE, Michaela; ABRAMOVICH, Carolina et al.Blood. 2002, Vol 100, Num 3, pp 862-868, issn 0006-4971Article